Vijay Kumar
Stock Analyst at Evercore ISI Group
(2.36)
# 2,461
Out of 5,182 analysts
289
Total ratings
45.11%
Success rate
-1.84%
Average return
Main Sectors:
Stocks Rated by Vijay Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EW Edwards Lifesciences | Maintains: Outperform | $92 → $93 | $84.15 | +10.52% | 17 | Apr 24, 2026 | |
| BSX Boston Scientific | Maintains: Outperform | $80 → $78 | $62.07 | +25.66% | 10 | Apr 23, 2026 | |
| ABT Abbott Laboratories | Maintains: Outperform | $134 → $120 | $91.13 | +31.68% | 20 | Apr 17, 2026 | |
| MDT Medtronic | Maintains: Outperform | $108 → $106 | $83.32 | +27.22% | 7 | Apr 9, 2026 | |
| MTD Mettler-Toledo International | Maintains: Outperform | $1,515 → $1,425 | $1,282.45 | +11.12% | 13 | Apr 6, 2026 | |
| USB U.S. Bancorp | Maintains: In-Line | $65 → $58 | $55.58 | +4.35% | 9 | Apr 6, 2026 | |
| TWST Twist Bioscience | Maintains: Outperform | $52 → $56 | $60.94 | -8.11% | 8 | Apr 6, 2026 | |
| TMO Thermo Fisher Scientific | Maintains: Outperform | $650 → $575 | $469.71 | +22.42% | 14 | Apr 6, 2026 | |
| SYK Stryker | Maintains: Outperform | $400 → $365 | $327.51 | +11.45% | 14 | Apr 6, 2026 | |
| ISRG Intuitive Surgical | Maintains: In-Line | $550 → $480 | $482.22 | -0.46% | 16 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $210 → $170 | $122.35 | +38.95% | 4 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $98 → $85 | $68.83 | +23.49% | 7 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $36 → $35 | $24.10 | +45.23% | 5 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $254 → $225 | $177.25 | +26.94% | 5 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $30 | $20.20 | +48.51% | 4 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $18 → $17 | $15.82 | +7.46% | 13 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $22 | $18.16 | +21.15% | 9 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $45 → $35 | $25.91 | +35.08% | 11 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $10 → $8.5 | $7.90 | +7.59% | 14 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $160 → $140 | $115.55 | +21.16% | 9 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $222 → $232 | $248.59 | -6.67% | 10 | Mar 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $340 → $360 | $329.89 | +9.13% | 3 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $112 → $118 | $86.77 | +35.99% | 4 | Feb 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $94 → $120 | $91.26 | +31.49% | 15 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $132 → $142 | $127.88 | +11.04% | 9 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $3 | $3.00 | - | 6 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $18 → $30 | $12.47 | +140.58% | 11 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $335 → $355 | $309.87 | +14.56% | 8 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $160 | $97.96 | +63.33% | 7 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $286 → $290 | $152.14 | +90.61% | 6 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.29 | +442.64% | 1 | May 31, 2022 |
Edwards Lifesciences
Apr 24, 2026
Maintains: Outperform
Price Target: $92 → $93
Current: $84.15
Upside: +10.52%
Boston Scientific
Apr 23, 2026
Maintains: Outperform
Price Target: $80 → $78
Current: $62.07
Upside: +25.66%
Abbott Laboratories
Apr 17, 2026
Maintains: Outperform
Price Target: $134 → $120
Current: $91.13
Upside: +31.68%
Medtronic
Apr 9, 2026
Maintains: Outperform
Price Target: $108 → $106
Current: $83.32
Upside: +27.22%
Mettler-Toledo International
Apr 6, 2026
Maintains: Outperform
Price Target: $1,515 → $1,425
Current: $1,282.45
Upside: +11.12%
U.S. Bancorp
Apr 6, 2026
Maintains: In-Line
Price Target: $65 → $58
Current: $55.58
Upside: +4.35%
Twist Bioscience
Apr 6, 2026
Maintains: Outperform
Price Target: $52 → $56
Current: $60.94
Upside: -8.11%
Thermo Fisher Scientific
Apr 6, 2026
Maintains: Outperform
Price Target: $650 → $575
Current: $469.71
Upside: +22.42%
Stryker
Apr 6, 2026
Maintains: Outperform
Price Target: $400 → $365
Current: $327.51
Upside: +11.45%
Intuitive Surgical
Apr 6, 2026
Maintains: In-Line
Price Target: $550 → $480
Current: $482.22
Upside: -0.46%
Apr 6, 2026
Maintains: Outperform
Price Target: $210 → $170
Current: $122.35
Upside: +38.95%
Apr 6, 2026
Maintains: Outperform
Price Target: $98 → $85
Current: $68.83
Upside: +23.49%
Apr 6, 2026
Maintains: Outperform
Price Target: $36 → $35
Current: $24.10
Upside: +45.23%
Apr 6, 2026
Maintains: Outperform
Price Target: $254 → $225
Current: $177.25
Upside: +26.94%
Apr 6, 2026
Maintains: Outperform
Price Target: $34 → $30
Current: $20.20
Upside: +48.51%
Apr 6, 2026
Maintains: In-Line
Price Target: $18 → $17
Current: $15.82
Upside: +7.46%
Apr 6, 2026
Maintains: Outperform
Price Target: $23 → $22
Current: $18.16
Upside: +21.15%
Apr 6, 2026
Maintains: Outperform
Price Target: $45 → $35
Current: $25.91
Upside: +35.08%
Apr 6, 2026
Maintains: In-Line
Price Target: $10 → $8.5
Current: $7.90
Upside: +7.59%
Apr 6, 2026
Maintains: Outperform
Price Target: $160 → $140
Current: $115.55
Upside: +21.16%
Mar 27, 2026
Maintains: Outperform
Price Target: $222 → $232
Current: $248.59
Upside: -6.67%
Feb 26, 2026
Maintains: Outperform
Price Target: $340 → $360
Current: $329.89
Upside: +9.13%
Feb 3, 2026
Maintains: Outperform
Price Target: $112 → $118
Current: $86.77
Upside: +35.99%
Jan 5, 2026
Upgrades: Outperform
Price Target: $94 → $120
Current: $91.26
Upside: +31.49%
Oct 31, 2025
Maintains: Outperform
Price Target: $132 → $142
Current: $127.88
Upside: +11.04%
May 19, 2025
Maintains: In-Line
Price Target: $3
Current: $3.00
Upside: -
Dec 2, 2024
Upgrades: Outperform
Price Target: $18 → $30
Current: $12.47
Upside: +140.58%
Oct 1, 2024
Maintains: In-Line
Price Target: $335 → $355
Current: $309.87
Upside: +14.56%
Oct 1, 2024
Maintains: Outperform
Price Target: $120 → $160
Current: $97.96
Upside: +63.33%
Oct 1, 2024
Maintains: Outperform
Price Target: $286 → $290
Current: $152.14
Upside: +90.61%
May 31, 2022
Initiates: Outperform
Price Target: $7
Current: $1.29
Upside: +442.64%